DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

AGEN-2385

Generic Name: AGEN-2385

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Phase 2

Active, not recruiting

Posted: 2023/09/28

Sponsor:University of Washin...

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Active, not recruiting

Posted: 2022/03/18

Sponsor:Incyte Biosciences I...

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Phase 2

Terminated

Posted: 2020/10/14

Sponsor:Incyte Corporation

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Phase 2

Active, not recruiting

Posted: 2020/07/09

Sponsor:Incyte Corporation

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Phase 1

Active, not recruiting

Posted: 2020/05/01

Sponsor:Incyte Corporation

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

BMS's Opdualag Shows Strong Early Performance as First LAG-3 Checkpoint Inhibitor for Melanoma

a month ago

Bristol-Myers Squibb's Opdualag, the first FDA-approved LAG-3 inhibitor combination, generated $58 million in second-quarter sales following its March approval for metastatic melanoma.

Pipeline Advances in Head and Neck Cancer Treatment: Over 100 Drugs in Development for 2025

2 months ago

DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.

LAG-3 Inhibitors Show Promise in Cancer Immunotherapy, Market Expected to Surge

8 months ago

The LAG-3 inhibitors market is poised for substantial growth, projected to exceed USD 3 billion by 2029, driven by increasing adoption in cancer therapy.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy